BDSX
Market cap | $62.55 Million |
---|---|
Enterprise Value | $138.69 Million |
Dividend Yield | $- (-) |
Earnings per Share | $-0.33 |
Beta | 0.98 |
Outstanding Shares | 146,656,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -1.52 |
---|---|
PEG | -24.94 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | 1.81 |
Enterprise Value to EBIT | -3.89 |
Enterprise Value to Net Income | -4 |
Total Debt to Enterprise | 0.7 |
Debt to Equity | 85.12 |
No data
No data
Biodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue analysis in the United States.